Santen

Exploring sirolimus as potential alternative therapy for persistent AMDAnti-vascular endothelial growth factor (VEGF) therapy is highly successful, but as Raj Maturi, MD, pointed out, also has some limitations.
Building on cyclosporine for dry eyeA phase II study investigating a novel topical cyclosporine product (CyclASol, Novaliq) formulated in a semifluorinated alkane (SFA) vehicle showed promising efficacy, safety, and tolerability. Planning is ongoing for the phase III trial of cyclosporine in the SFA technology.
Current Approaches in the Management of Glaucoma PatientsExplore factors affecting patient compliance.
Santen to acquire InnFocus, developer of glaucoma drainage implantSanten Pharmaceutical will soon acquire InnFocus, developer of a glaucoma implant device (InnFocus Microshunt), for $225 million, according to a definitive agreement from the two companies.
Anti-VEGF drugs: Safe and effective for treating DMEData from large randomized trials indicate that diabetic macular edema can be treated safely and effectively with anti-vascular endothelial growth factor therapies.
Santen launches new preservative-free combination eye drop in the UKSanten recently launched fixed-combination tafluprost and timolol (TAPTIQOM) in the United Kingdom.
Pharmacokinetics data suggests sirolimus activity confined to eyeSerial measurements of sirolimus blood concentrations after intravitreal injection show the maximum concentration achieved was below the level generally associated with systemic immunosuppression.
Santen purchases ophthalmic assets from MerckSanten Pharmaceutical recently announced that it has entered into an agreement with Merck & Co. to purchase Merck's ophthalmology products—Cosopt (dorzolamide/timolol), Cosopt PF, Trusopt (dorzolamide), Trusopt PF, Timoptic (timolol maleate ophthalmic solution), Timoptic PF, Timoptic XE (timolol maleate ophthalmic gel), Saflutan (tafluprost), and Taptiqom(tafluprost timolol)—in Japan, Europe, and Asia Pacific.
DES market expected to grow about $4 billion in 10 yearsAs dry eye syndrome (DES) affects more and more patients over the next 10 years, pharmaceutical companies are expecting to expand their clinical products globally to treat the condition, thus tripling the market’s global revenue over the next decade.